InvestorsHub Logo
Followers 71
Posts 11465
Boards Moderated 0
Alias Born 12/25/2009

Re: None

Wednesday, 04/11/2018 2:58:43 PM

Wednesday, April 11, 2018 2:58:43 PM

Post# of 8305
Head to Head Review: Tonix Pharmaceuticals (TNXP) versus The Competition

Posted by Joseph McCarthy on Apr 11th, 2018 // No Comments

Tonix Pharmaceuticals (NASDAQ: TNXP) is one of 484 public companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its rivals? We will compare Tonix Pharmaceuticals to similar businesses based on the strength of its valuation, profitability, analyst recommendations, institutional ownership, dividends, risk and earnings.

Profitability

This table compares Tonix Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Tonix Pharmaceuticals N/A -74.46% -69.58%
Tonix Pharmaceuticals Competitors -3,102.68% -152.82% -26.71%

Risk & Volatility

Tonix Pharmaceuticals has a beta of 2.85, indicating that its share price is 185% more volatile than the S&P 500. Comparatively, Tonix Pharmaceuticals’ rivals have a beta of 1.08, indicating that their average share price is 8% more volatile than the S&P 500.

Earnings and Valuation

This table compares Tonix Pharmaceuticals and its rivals revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Tonix Pharmaceuticals N/A -$21.12 million -1.05
Tonix Pharmaceuticals Competitors $2.03 billion $132.97 million -3.45
Tonix Pharmaceuticals’ rivals have higher revenue and earnings than Tonix Pharmaceuticals. Tonix Pharmaceuticals is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Insider and Institutional Ownership

15.4% of Tonix Pharmaceuticals shares are owned by institutional investors. Comparatively, 47.7% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 4.0% of Tonix Pharmaceuticals shares are owned by insiders. Comparatively, 14.9% of shares of all “Pharmaceutical preparations” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Tonix Pharmaceuticals and its rivals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tonix Pharmaceuticals 0 0 4 0 3.00
Tonix Pharmaceuticals Competitors 2761 8456 21244 566 2.59
Tonix Pharmaceuticals presently has a consensus target price of $8.33, indicating a potential upside of 174.12%. As a group, “Pharmaceutical preparations” companies have a potential upside of 44.66%. Given Tonix Pharmaceuticals’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Tonix Pharmaceuticals is more favorable than its rivals.

Summary

Tonix Pharmaceuticals beats its rivals on 7 of the 13 factors compared.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals engages in developing pharmaceutical and biological products to address public health challenges. Its lead product candidate, TNX-102 SL or Tonmya, designed as a bedtime treatment for posttraumatic stress disorder (PTSD), which is in Phase 3 study in the military-related PTSD population. The company is also developing TNX-601 (tianeptine oxalate), a clinical candidate at pre-IND (investigational new drug) application stage, designed as a daytime treatment for posttraumatic stress disorder (PTSD); and TNX-801, a live synthetic version of horsepox virus, at the pre-IND application stage. Tonix Pharmaceuticals Holding Corp. was founded in 2007 and is based in New York, New York.
__________________________________________________
https://theenterpriseleader.com/2018/04/11/head-to-head-review-tonix-pharmaceuticals-tnxp-versus-the-competition.html

Interesting, but can't verify the info.

TNXP
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent TNXP News